Research Topics
Species | M DreylingSummaryAffiliation: University of Munich Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European Martin Dreyling
Department of Internal Medicine III, Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
Blood 105:2677-84. 2005..18). Early consolidation by myeloablative radiochemotherapy followed by ASCT is feasible and results in a significant prolongation of PFS in advanced-stage MCL. Longer follow-up is needed to determine the effect on OS...
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphomaM Dreyling
Department of Medicine III, University Hospital, LMU Munich, Germany
Ann Oncol 24:857-77. 2013..A first report had focused on diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia...- Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling
Department of Medicine III, University Hospital Großhadern LMU Munich, Germany
Leuk Lymphoma 54:699-707. 2013..At the annual conference in Lisbon, recent results of molecular pathogenesis, analyses of current clinical trials and new study concepts were discussed... - Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling
Department of Medicine III, University Hospital Grosshadern LMU Munich, Munich, Germany
Leuk Lymphoma 52:2226-36. 2011..At the annual conference in Warsaw, recent results of molecular pathogenesis, analyses of current clinical trials and new study concepts were discussed... - Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conferenceMartin Dreyling
Department of Medicine III, University Hospital Grosshadern LMU Munich, Munich, Germany
Leuk Lymphoma 51:1612-22. 2010..At the recent annual conference in Jerusalem, recent results of molecular pathogenesis, analyses of current clinical trials, and new study concepts were discussed... - Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?Martin Dreyling
University Hospital Grosshadern, Department of Internal Medicine III, Ludwig Maximilians University, Munich, Germany
Curr Opin Oncol 20:487-94. 2008..Conventional-dosed chemotherapy achieves only temporary responses with a median duration of remissions of only 1-2 years... - [Up-to-date treatment of follicular lymphomas]M Dreyling
Medizinische Klinik III, , Grosshadern
Dtsch Med Wochenschr 130:2149-54. 2005 - Combination of biologicals in indolent lymphoma: finally the end of chemotherapy era in indolent lymphoma?Martin Dreyling
Medizinische Klinik III der Universität Münich Grosshadern, Germany
Leuk Lymphoma 49:8-9. 2008 - Hyper-CVAD in mantle-cell lymphoma: really "hyper" or just hype?Martin Dreyling
Department of Medicine III, University of Munich Campus, Grosshadern, Germany
Leuk Lymphoma 49:1017-8. 2008 - [Therapy of mantle cell lymphoma]M Dreyling
Med Klinik und Poliklinik III, Klinikum der Universitat Munchen Grosshadern, Marchioninistrasse 15, 81377, Munchen, Deutschland
Internist (Berl) 48:382-8. 2007..However, numerous molecular targeting strategies (e.g. proteasome inhibitors, immunomodulatory drugs or radiolabeled antibodies) have achieved promising results in early phase II studies... - Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapyM Dreyling
Department of Medicine III, Grosshadern, Ludwig Maximilians University, Munich, Germany
Ann Hematol 86:81-7. 2007..Current study concepts evaluate the role of RIT consolidation in combination with antibody maintenance to achieve a potentially curative approach even in patients with advanced stage disease... - [Current strategies in the treatment of advanced stage mantle cell lymphoma]G Lenz
Medizinische Klinik III, Klinikum der Ludwig Maximilians Universität, Munchen
Dtsch Med Wochenschr 129:2429-33. 2004..g. proteasome inhibitors or radiolabeled antibodies) are urgently warranted to further improve the long-term outcome of MCL... - Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphomaO Weigert
Department of Internal Medicine III, University of Munich, University Hospital Grosshadern, Munich, Germany
Leukemia 21:524-8. 2007..Interestingly, efficacy in vitro correlated with sequence of treatment, indicating that pretreatment with cytarabine, followed by proteasome inhibition, may be the preferred approach... - Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study GroupC Nickenig
Department of Internal Medicine III, Ludwig Maximilians University, Munich Grosshadern, Germany
Ann Oncol 18:136-42. 2007.... - The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study GroC Buske
Department of Internal Medicine III, University of Munich, Munich, Germany
Leukemia 23:153-61. 2009..0241). There was no major difference of treatment-associated toxicity between both treatment groups. These data indicate that the addition of rituximab to front-line chemotherapy improves treatment outcome in patients with LPL or WM... - Current treatment standards and future strategies in mantle cell lymphomaM Dreyling
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany
Ann Oncol 19:iv41-4. 2008 - Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicularRoswitha Forstpointner
Department of Internal Medicine III, University of Munich, Grosshadern Marchioninistr. 15, , Germany
Blood 108:4003-8. 2006..035) and MCL (P = .049) separately. Hence, R-maintenance is effective after salvage with R-chemotherapy and significantly prolongs response duration in patients with recurring or refractory FL or MCL... - Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lyChristina Nickenig
Department of Internal Medicine III, Ludwig-Maximilians University, Munich Grosshadern, Germany
Cancer 107:1014-22. 2006..Particularly in younger, high-risk patients who are candidates for autologous stem cell transplantation, CHOP should be preferred over MCP... - Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphomaM Dreyling
Department of Internal Medicine III, Grosshadern Hospital, Ludwig-Maximilians University, Munich, Germany
Ann Oncol 16:ii99-104. 2005 - The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell Roswitha Forstpointner
Department of Internal Medicine III, University of Munich, Klinikum Grosshadern, , Germany
Blood 104:3064-71. 2004..0042). There were no differences in clinically relevant side effects in both study arms. Hence, the addition of rituximab to FCM chemotherapy significantly improves the outcome of relapsed or refractory FL and MCL... - Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results oGeorg Lenz
Department of Internal Medicine III of the Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
J Clin Oncol 23:1984-92. 2005..Hence, R-CHOP may serve as a new baseline regimen for advanced stage MCL, but needs to be further improved by novel strategies in remission... - Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study GroupGeorg Lenz
Department of Internal Medicine III, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany
Blood 104:2667-74. 2004..Longer follow-up is necessary to determine the effect of ASCT on overall survival... - Investigational strategies in autologous stem cell transplantation for follicular lymphomaOliver Weigert
Department of Internal Medicine III, Ludwig-Maximilians-University, Munich, Germany
Curr Oncol Rep 8:368-75. 2006..Combination of these novel strategies into a multimodal approach justifies hope that the treatment outcome of patients suffering from follicular lymphoma will be further improved... - [Current clinical aspects of follicular lymphoma]Martin Dreyling
Medizinische Klinik III, Klinikum der Universität München Campus Großhadern, Munchen
Ther Umsch 67:511-6. 2010..Accordingly, current series report on an improved median overall survival of 15-20 years... - Mantle cell lymphoma: established therapeutic options and future directionsG Lenz
Department of Internal Medicine III, Grosshadern Hospital, Ludwig Maximilians University, 81377 Munich, Germany
Ann Hematol 83:71-7. 2004..Thus, new therapeutic strategies such as radioactively labeled antibodies or molecular targeting agents (e.g. Bortezomib or flavopiridol) are urgently warranted to further improve the clinical outcome of mantle cell lymphoma... - Therapy of mantle cell lymphoma: current standards and future strategiesChristian Schmidt
Department of Medicine III, University of Munich, Hospital Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
Hematol Oncol Clin North Am 22:953-63, ix. 2008..New concepts of therapy are urgently warranted, including new molecular approaches, such as bortezomib, thalidomide, lenalidomide, and temsirolimus... - [Prophylaxis and differential therapy of tumorlysis syndrome]M Krych
Medizinische Klinik und Poliklinik III-Grosshadern, , Munich
Dtsch Med Wochenschr 129:1440-5. 2004 - Current management of follicular lymphomasWolfgang Hiddemann
Department of Internal Medicine III, University of Munich, Munich, Germany
Br J Haematol 136:191-202. 2007..New therapeutic perspectives have also emerged from increasing insights into the biology of the disease that unravel molecular targets for novel agents, some of which have entered clinical evaluation already... - Current management of mantle cell lymphomaOliver Weigert
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
Drugs 67:1689-702. 2007..This article addresses these issues providing relevant information for current state-of-the-art management of patients with mantle cell lymphoma and giving a perspective of upcoming treatment strategies... - Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cellsValeria Milani
Department of Medical Oncology, University Medical Center Grosshadern, 81377 Munich, Germany
Int J Hyperthermia 25:262-72. 2009..In conclusion, these results suggest that the application of bortezomib, under thermal conditions, in mantle cell lymphoma cells may be beneficial and warrants further investigation... - A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation studyOliver Weigert
Department of Internal Medicine III, University of Munich, Munich, Germany
Leuk Lymphoma 50:716-22. 2009..Median progression free and overall survival were 5 and 15.5 months, respectively. The combination of bortezomib and a high-dose cytarabine-containing regimen has activity in heavily pretreated patients with relapsed or refractory MCL... - 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphomaMarc Weinkauf
CCG Leukemia, Department of Medicine III, University Hospital Grosshadern LMU, Munich, Germany, in association with Helmholtz Center Munich, Munich, Germany
Electrophoresis 30:974-86. 2009..The results were confirmed in primary mantle cell lymphoma, thus confirming the critical role of these candidate proteins of proteasome inhibition... - Treatment strategies in follicular lymphomas: current status and future perspectivesWolfgang Hiddemann
Department of Internal Medicine III, University of Munich, Marchioninistr 15, 81377 Munich, Germany
J Clin Oncol 23:6394-9. 2005..New therapeutic perspectives also emerge from increasing insights into the biology of the disease that unravel molecular targets for novel agents, some of which have entered clinical evaluation already... - Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: rWolfgang Hiddemann
Department of Internal Medicine III, University of Munich, Grosshadern Marchioninistr 15, 81377 Munchen, Germany
Blood 106:3725-32. 2005..Hence, adding rituximab to CHOP significantly improves the outcome for patients with previously untreated advanced-stage FL and does not induce major adverse effects... - Transplantation strategies for patients with follicular lymphomaChristian Buske
Department of Internal Medicine III, University of Munich, GroBhadern, Germany
Curr Opin Hematol 12:266-72. 2005.... - Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?Georg Lenz
Lymphoma Section, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
Nat Clin Pract Oncol 2:72-3. 2005 - [Monoclonal antibody therapy for malignant lymphoma]Christian Buske
Medizinische Klinik III, Klinikum der Universitat Munchen, Grosshadern, Marchioninistrasse 15, 81377 Munchen
Med Klin (Munich) 100:14-24. 2005.... - Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study GroGeorg Lenz
Department of Internal Medicine III, Ludwig Maximilians University, University Hospital Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany
J Clin Oncol 22:4926-33. 2004.... - The role of fludarabine in the treatment of follicular and mantle cell lymphomaGeorg Lenz
Department of Internal Medicine III, Grosshadern Hospital, Ludwig Maximilians University, Munich, Germany
Cancer 101:883-93. 2004..Consequently, current research efforts have focused on the use of fludarabine-containing combinations in the first-line treatment of FL and MCL... - Current status and perspective of antibody therapy in follicular lymphomaChristian Buske
Department of Internal Medicine III, Grosshadern Hospital, Ludwig Maximilians University, Munich, Germany
Haematologica 91:104-12. 2006.... - The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincChristian Buske
Department of Internal Medicine III, University of Munich, Grosshadern, Marchioninistr 15, 81377 Munchen, Germany
Blood 108:1504-8. 2006..001). Our data demonstrate that the FLIPI is able to identify high-risk patients with advanced-stage FL after first-line treatment with rituximab/chemotherapy... - Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemiaGeorg Lenz
Department of Internal Medicine III, Grosshadern Hospital, Ludwig Maximilians University, Munich, Germany
Ann Hematol 83:628-33. 2004..The reduced mRNA expression in additional samples may indicate an involvement of hMLH1 in the malignant transformation in a small subset of cases. In contrast, MGMT does not seem to be involved in the pathogenesis of AML... - Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangementMirjam Klaus
Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, 81377 Munich, Germany
Cancer Genet Cytogenet 144:36-43. 2003..Compared to translocations involving MLL and other partner genes, complex rearrangements are unique for MLL-AF10 fusions. This may result from the opposite orientation of MLL and AF10... - Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-upM Dreyling
Department of Medicine III, University Hospital Grosshadern, Munich, Germany
Ann Oncol 19:ii77-8. 2008 - A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster
Department of Internal Medicine III, University of Munich, Germany
Blood 111:558-65. 2008..The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL... - Mantle cell lymphoma: state-of-the-art management and future perspectiveOliver Weigert
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
Leuk Lymphoma 50:1937-50. 2009..This article will provide relevant information for decision making in clinical practice and give a perspective on upcoming management strategies... - Mantle cell lymphoma: therapeutic strategies are different from CLLWolfgang Hiddemann
Department of Medicine III, University Hospital Grosshadern/LMU, Marchioninistrasse 15, 81377 Munich, Germany
Curr Treat Options Oncol 4:219-26. 2003..Prospective randomized trials remain critical to further improve the clinical course of MCL with the addition of newer treatment modalities, such as radioactively labeled antibodies and targeted therapies (eg, flavopiridol and PS-341)... - Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression backgroundMarc Weinkauf
Department of Medicine III, University Hospital Grosshadern/LMU, Munich, Germany
Electrophoresis 27:4555-8. 2006.... - 3'UTR mediated regulation of the cyclin D1 proto-oncogeneAnagha Deshpande
Department of Medicine III, Klinikum Grosshadern, Munich, Germany
Cell Cycle 8:3584-92. 2009.... - Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphomaMarc Weinkauf
CCG Leukemia, Department of Medicine III, University Hospital Grosshadern LMU, Munich, Germany
Electrophoresis 28:4416-26. 2007..36). Most interestingly, additional data bank search identified 13 out of 17 referenced proteins (76%) as members of a TP53-dependent network of cell regulation... - Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphomaOliver Weigert
Department of Internal Medicine III, University of Munich, Munich, Germany
Cancer 107:686-95. 2006.... - Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferationG Hutter
Department of Medicine III, University Hospital Grosshadern LMU, CCG Leukemia, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Munich, Germany
Ann Hematol 88:821-8. 2009..This proliferation-dependent network of oncogenic alterations complements the previously identified proliferation expression signature described by RNA expression profiling in MCL... - Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cellTiemo Katzenberger
Institute of Pathology, University of Wurzburg, Department of Medicine III, University Hospital Grosshadern LMU München, Germany
Blood 101:699-702. 2003..On the basis of these findings, CD5(+) DLBLs are likely to arise from the same progenitor cell as the mutated variant of CD5(+) lymphocytic lymphoma/B-cell chronic lymphocytic leukemia (B-CLL)... - Use of polymorphisms in the noncoding region of the human mitochondrial genome to identify potential contamination of human leukemia-lymphoma cell linesGrit Hutter
Department of Medicine III, University Hospital Grosshadern LMU, GSF Clinical Cooperative Group Leukemia, Germany
Hematol J 5:61-8. 2004..In comparison to other methods (cytogenetics, fluorescence in situ hybridization or immunophenotyping), this technique is less laborious and time consuming... - Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphomaGrit Hutter
Department of Medicine III, University Hospital Grosshadern/LMU, CCG Leukemia, GSF-National Research Center for Environment and Health, Munich, Germany
Genes Chromosomes Cancer 45:203-10. 2006..The rare p16(INK4a) promoter methylation and p16(INK4a) genetic alterations were directly correlated to cell proliferation and therefore are regarded as additional molecular alterations involved in the cell-cycle dysregulation of MCL... - Improvement of overall survival in advanced stage mantle cell lymphomaAnnina Herrmann
Department of Internal Medicine III, University of Munich, Germany
J Clin Oncol 27:511-8. 2009..To explore a potential progress in outcome a historical comparison was performed using data from the Kiel Lymphoma Study Group (KLSG; 1975 to 1986) and the German Low Grade Lymphoma Study Group (GLSG; 1996 to 2004)... - Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin diseaseBärbel Seyfarth
Department of Internal Medicine I, Westpfalz Klinikum, Kaiserslautern, Germany
Br J Haematol 133:3-18. 2006..We focus on follicular lymphoma, diffuse large B-cell lymphoma and Hodgkin disease since these are most frequent and evidence-based salvage strategies are beginning to emerge... - Indolent lymphomas: current and emerging treatment approachesDavid Maloney
Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109, USA
Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006.... - Revised response criteria for malignant lymphomaBruce D Cheson
Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
J Clin Oncol 25:579-86. 2007..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies... - Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaChristiane Pott
Second Medical Department, University Hospital Schleswig Holstein, Campus Kiel, Chemnitzstr 33, 24116 Kiel, Germany
Blood 107:2271-8. 2006..We conclude that sequential quantitative monitoring of residual disease after ASCT is a powerful indicator for treatment outcome in MCL and defines subgroups of patients with a significantly different prognosis... - Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisHolger Schulz
Cochrane Haematological Malignancies Group, Clinic I of Internal Medicine I, University of Cologne, Kerpenerstrasse 62, D 50924 Cologne, Germany
J Natl Cancer Inst 99:706-14. 2007.... - High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Rudolf Weide
Praxisklinik for Hematology and Oncology, Koblenz, Germany
Leuk Lymphoma 48:1299-306. 2007..BMR is a very effective new outpatient immuno-chemotherapy with low toxicity for patients with relapsed/refractory FL, MCL and other indolent lymphomas... - Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinationsSebastian Böttcher
Second Department of Medicine, Chemnitzstrasse 33, D 24116 Kiel, Germany
Haematologica 93:551-9. 2008..Data from prospective clinical trials comparing the clinical applicability of flow cytometry to routine diagnostic methods and to polymerase chain reaction are currently lacking... - Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study GroupWolfram Klapper
Department of Pathology, Hematopathology Section and Lymph Node Registry, Kiel, Germany
J Clin Oncol 25:3330-6. 2007..Several histopathologic biomarkers for risk stratification have been suggested, but most markers have not been validated in patients treated in prospective trials... - Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent eventsGerhard Herzog
Haematologica 90:693-5. 2005..We performed allelotyping and p53 mutation analysis in 75 patients with morphologically and cytogenetically classified AML... - Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study GroupOlaf Determann
Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
Blood 111:2385-7. 2008..013). Thus, the Ki-67 index remains an important prognostic marker in the era of anti-CD20 therapy. The Euro-pean MCL study is registered at www.ClinicalTrials.gov as #NCT00016887... - Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphomaInga Nieländer
Haematologica 93:949-50. 2008 - Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximabRalf U Trappe
Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
Transplantation 84:1708-12. 2007..Single-agent rituximab salvage therapy is an effective treatment option in this setting of intensively pretreated patients, with virtually no therapy-associated toxicity... - Rituximab plus chemotherapy in follicular and mantle cell lymphomasWolfgang Hiddemann
University of Munich, Germany
Semin Oncol 30:16-20. 2003..A trend towards longer overall and disease-free survival for rituximab plus FCM has been observed, but longer follow-up is required... - Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissueElena Hartmann
Institute of Pathology, University of Wurzburg, Wurzburg, Germany
J Clin Oncol 26:4966-72. 2008....